Cargando…

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

Detalles Bibliográficos
Autores principales:	Darsalia, Vladimer, Larsson, Martin, Klein, Thomas, Patrone, Cesare
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822625/ https://www.ncbi.nlm.nih.gov/pubmed/29466979 http://dx.doi.org/10.1186/s12933-018-0674-3

Ejemplares similares

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride
por: Darsalia, Vladimer, et al.
Publicado: (2013)

The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
por: Chiazza, Fausto, et al.
Publicado: (2018)

Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4
por: Lietzau, Grazyna, et al.
Publicado: (2016)

Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
por: Darsalia, Vladimer, et al.
Publicado: (2019)

The Stroke-Induced Increase of Somatostatin-Expressing Neurons is Inhibited by Diabetes: A Potential Mechanism at the Basis of Impaired Stroke Recovery
por: Chiazza, Fausto, et al.
Publicado: (2020)

DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes–Induced Blood–Brain Barrier Leakage and Normalize Capillary Pericyte Coverage
por: Elabi, Osama F., et al.
Publicado: (2023)

Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
por: Lietzau, Grazyna, et al.
Publicado: (2018)

The Pre-Stroke Induction and Normalization of Insulin Resistance Respectively Worsens and Improves Functional Recovery
por: Vercalsteren, Ellen, et al.
Publicado: (2023)

Diet-induced weight loss in obese/diabetic mice normalizes glucose metabolism and promotes functional recovery after stroke
por: Karampatsi, Dimitra, et al.
Publicado: (2021)

Normalisation of glucose metabolism by exendin‐4 in the chronic phase after stroke promotes functional recovery in male diabetic mice
por: Augestad, Ingrid Lovise, et al.
Publicado: (2021)

Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study
por: Zabala, Alexander, et al.
Publicado: (2021)

GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals
por: Larsson, Martin, et al.
Publicado: (2019)

Western Diet Accelerates the Impairment of Odor-Related Learning and Olfactory Memory in the Mouse
por: Lietzau, Grazyna, et al.
Publicado: (2020)

The selective alpha7 nicotinic acetylcholine receptor agonist AR-R17779 does not affect ischemia–reperfusion brain injury in mice
por: Hammarlund, Maria E., et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats
por: Darsalia, Vladimer, et al.
Publicado: (2012)

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
por: Brown, Dominique Xavier, et al.
Publicado: (2012)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
por: Vitale, Cristiana, et al.
Publicado: (2016)

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
por: Dicembrini, Ilaria, et al.
Publicado: (2011)

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
por: Brunton, S
Publicado: (2014)

Recently published papers: Tracheostomy: why rather than when? Obesity: does it matter? And stroke: diagnosis, thrombosis and prognosis
por: McCormick, Tim, et al.
Publicado: (2007)

Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization
por: Darsalia, Vladimer, et al.
Publicado: (2014)

A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia
por: Lietzau, Grazyna, et al.
Publicado: (2021)

Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4
por: Larsson, Martin, et al.
Publicado: (2016)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
por: Goggins, Michael
Publicado: (2012)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Inborn errors of immunity to infection: the rule rather than the exception
por: Casanova, Jean-Laurent, et al.
Publicado: (2005)

Wild mammals through the lens of biomass rather than biodiversity
por: Damuth, John
Publicado: (2023)

Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
por: Østergaard, Jakob A., et al.
Publicado: (2022)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
por: Longato, Enrico, et al.
Publicado: (2020)

The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study
por: Al-Mashhadi, Zheer Kejlberg, et al.
Publicado: (2022)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
por: Gonzalez, Jimmy, et al.
Publicado: (2023)

Female Genital Arousal: A Focus on How Rather than Why
por: Dewitte, Marieke
Publicado: (2020)

Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
por: Schwarzschild, Michael A.
Publicado: (2017)

Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists
por: Laux, Gunter, et al.
Publicado: (2016)

Acne Scarring: Why We Should Act Sooner Rather Than Later
por: Dréno, Brigitte, et al.
Publicado: (2021)

Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors
por: Yanagawa, Tatsuo
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_su1dcg43cpojl8i6eu9kee38vv